Diethanolamine → N,N-bis(2-hydroxyethyl)-2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxamide
Reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19](O)=[O:20])=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[NH:28]([CH2:32][CH2:33][OH:34])[CH2:29][CH2:30][OH:31]>>[OH:31][CH2:30][CH2:29][N:28]([CH2:32][CH2:33][OH:34])[C:19]([C:17]1[S:18][C:13]2[C:12]([N:22]3[CH2:23][CH2:24][O:25][CH2:26][CH2:27]3)=[N:11][C:10]([C:5]3[CH:6]=[CH:7][CH:8]=[C:9]4[C:4]=3[CH:3]=[N:2][NH:1]4)=[N:15][C:14]=2[CH:16]=1)=[O:20]Participants
3
Procedure
2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid 13 (30 mg) was coupled to diethanolamine via General Procedure B. The product was purified via reverse phase HPLC to give 15.8 mg of 258. MS (Q1) 468.8 (M)+.
Workup
- customThe product was purified via reverse phase HPLC
Sources & evidence
- ORD record
- ord-6a96d5f3de9443ecafa800b48cfc448e
- Source dataset
- uspto-grants-2013_05
- Patent number
- US08450315B2
Reaction notes
Loading…